Home Equities Score Vaxart, Inc. (VXRT) Stock Prices Skyrocket Following Announcement of T-cell Webinar

Vaxart, Inc. (VXRT) Stock Prices Skyrocket Following Announcement of T-cell Webinar

Vaxart, Inc. (VXRT) stock prices were up a staggering 37.46% as of market close on April 27th, 2021, bringing the price per share up to USD$8.33.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

Novel COVID-19 Tablet

With the world hurtling towards COVID-19 solutions for the pandemic, VXRT is setting itself apart from its competitors with a drug, VXA-CoV2-1, that comes in tablet form rather than via injections. This circumvents the issue of the transportation of typical covid injections being a costly endeavor. Furthermore, it could facilitate the acceleration of universal immunizations because the administration of a tablet does not require specialized healthcare professionals in the way injections do.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Read More

Competitive Advantage of VXA-CoV2-1

Another massive differentiator of VXRT’s VXA-CoV2-1 is that it has the potential to be effective against the various strains of the COVID-19 virus that are emerging and are proving to be resistant to typical injection-based vaccinations. With the drug targeting nucleoprotein (N) as well as spike proteins (S), a significant T-cell response has been observed as a target of the N protein. This is significant because a potent T-cell response has the potential to offer protection against even more severe covid symptoms.

Additional Developments

So far, the drug has met its primary endpoint as well as all of its secondary endpoints in the first phase of its trial. VXRT has been collaborating with Kindred Biosciences for the manufacturing of various COVID-19 vaccine candidates, including VXA-CoV2-1. Under a recently expanded agreement, the plant located in California will see the scaling of clinical trial material into mid-size bioreactors. The agreement will also see the single-use bioreactors in the Kansas plant being used for manufacturing at a 2000L scale.

Agreement with Attwill

An agreement has also been entered with Attwill Vascular Technologies that will facilitate the processing and lyophilizing of specific compounds, as well as the tableting of the lyophilized compounds for use in VXA-CoV2-1. To capitalize on recent developments, the company has increased its workforce to 49 full-time employees, with hiring have been primarily conducted in R&D, clinical, regulatory manufacturing, and financial areas.

Promising Liquidity Position

December 31st, 2020 saw the company report cash and cash equivalents of USD$126.9 million, a monumental increase from the USD$13.5 million reported as of December 31st 2019. The healthy liquidity position is attributable to the USD$97 million netted from the company’s USD$100 million at-the-market facility from June 2020; the exercising of warrants, which netted VXRT USD$26 million; USD$9.2 having been raised from a registered direct offering in March 2020; and USD$4.9 million from VXRT’s USD$250 million at-the-market facility from October 2020.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

Future Outlook for VXRT

The success of Phase 1 of VXA-CoV2-1’s clinical trial has boosted investor confidence, who continue to back the company as it gears up for Phase 2. With such promising results, partnerships to facilitate the hopeful commercial production of the drug, and a solid liquidity position, the company is poised to leverage its resources to come out ahead in the COVID-19 vaccine race. Both current and prospective shareholders are hopeful for the future of the company, as evidence by recent surges in VXRT stock prices.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Havertys Furniture Companies Inc. (HVT) stock gains during after-hour trading, Here’s to know why?

Havertys Furniture Companies Inc. (NASDAQ: HVT) stock declined by 0.39% at last close whereas the HVT stock price gains by 4.6% in the after-hours...

Oragenics Inc. (OGEN) stock gained during current market. What’s driving it high?

Oragenics Inc. (OGEN) stock gains by 54.33% during the current market trading session. Oragenics, is a research and development firm focused on combating infectious...

Flora Growth Corp. (FLGC) stock declines during premarket. Here’s what you should know?

Flora Growth Corp. (NASDAQ: FLGC) stock gained by 49.67% at last close whereas the FLGC stock price plunged by 18.36% in the pre-market trading...

Palatin Technologies Inc. (PTN) stock rises during pre-market trading. What has been happening lately?

Palatin Technologies Inc. (NASDAQ: PTN) stock declined by 1.16% the last close whereas the PTN stock price gains by 3.91% in the pre-market trading...

Smith Micro Develops Inc. (SMSI) stock soars during current market trading. Here’s to know why?

Smith Micro Develops Inc. (NASDAQ: SMSI) stock surged by 2.39% during the current market trading session. Smith Micro creates software that simplifies and improves...

Relmada Therapeutics Inc. (RLMD) stock is plunging in the current trading session; What’s going on?

In the current trading session, Relmada Therapeutics Inc. (RLMD) stock shares are plunging by -5.97%. The current trading price is at $23.62 in the...

Oragenics Inc. (OGEN) stock gained during current market. What’s driving it high?

Oragenics Inc. (OGEN) stock gains by 54.33% during the current market trading session. Oragenics, is a research and development firm focused on combating infectious...

Tonix Pharmaceutics Holdings Inc. (TNXP) stock gains during current market. What’s driving it high?

Tonix Pharmaceuticals Holdings Inc. (TNXP) stock gains by 2.81% in the current market trading session. Tonix is a clinical-stage biopharmaceutical business dedicated on finding,...

Related News

Tonix Pharmaceutics Holdings Inc. (TNXP) stock gains during current market. What’s driving it high?

Tonix Pharmaceuticals Holdings Inc. (TNXP) stock gains by 2.81% in the current market trading session. Tonix is a clinical-stage biopharmaceutical business dedicated on finding,...

NanoVibronix Inc. (NAOV) stock fell during after-market. Let’s find out why?

NanoVibronix Inc. (NAOV) stock plunged by 27.2% at the last close while the NAOV stock price fell by 8.42% in the after-hours trading session....

China Online Education Group Inc. (COE) stock fell during current market. Here’s the update

China Online Education Group Inc. (COE) stock declines by 13.91% in the current market trading. China Online Education Group is a major Chinese online...

Abeona Therapeutics Inc. (ABEO) stock surged during current market trading. Why so?

Abeona Therapeutics Inc. (ABEO) stock gains by 6.63% in the current market trading session. Abeona Therapeutics Inc. is a pharmaceutical firm in the early...

17 Education & Technology Group Inc. (YQ) stock plummeting continues on Monday pre-market but why?

17 Education & Technology Group Inc. (YQ) stock has declined 21.28% as of this writing in Monday,s pre-market. In the regular trading session on...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam